Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Freeport-McMoRan Inc. due to allegations of violations of federal securities laws related to safety issues at the Grasberg Block Cave mine in Indonesia, which resulted in significant investor losses [2][5]. Group 1: Allegations and Legal Actions - The complaint alleges that Freeport and its executives made false or misleading statements and failed to disclose safety inadequacies at the Grasberg Block Cave mine, which heightened risks of worker fatalities and regulatory issues [5]. - Investors who purchased Freeport securities between February 15, 2022, and September 24, 2025, are encouraged to discuss their legal rights with Faruqi & Faruqi [2][5]. Group 2: Incident and Stock Price Impact - On September 9, 2025, Freeport suspended mining activities at the Grasberg mine after an incident trapped seven workers, leading to a stock price drop of $2.77, or 5.9%, closing at $43.89 per share [6]. - Following the tragic update on September 24, 2025, that two trapped workers were fatally injured, Freeport's stock fell by $7.69, or 17%, closing at $37.67 per share [7]. - An article published on September 25, 2025, highlighted potential strains in Freeport's relationship with the Indonesian government, causing the stock to drop another $2.33, or 6.2%, to close at $35.34 [8]. Group 3: Expert Opinions and Class Action Details - An expert stated that the landslide incident at Freeport was preventable and should have been anticipated, raising concerns about the company's safety protocols [9]. - The deadline for investors to seek the role of lead plaintiff in the federal securities class action against Freeport is January 12, 2026 [2].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. due to allegations of violations of federal securities laws related to misleading statements and undisclosed adverse facts affecting the company's financial performance [2][5]. Summary by Sections Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Molina to contact them regarding their legal options, particularly for those who purchased securities between February 5, 2025, and July 23, 2025 [1][2]. Allegations Against Molina - The complaint alleges that Molina and its executives made false or misleading statements and failed to disclose critical information, including: - Material adverse facts regarding the company's medical cost trend assumptions [5]. - A dislocation between premium rates and medical costs [5]. - Dependency on low utilization of behavioral health, pharmacy, and inpatient and outpatient services for near-term growth [5]. - Likelihood of substantial cuts to financial guidance for fiscal year 2025 [5]. - Misleading positive statements about the company's business and prospects [5]. Financial Performance and Stock Impact - On July 7, 2025, Molina announced second-quarter financial results, revealing adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines. The company cut its full-year adjusted earnings guidance by 10.2%, from at least $24.50 per share to a range of $21.50 to $22.50 per share [6]. - Following this announcement, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share on July 7, 2025, with unusually heavy trading volume [6]. - On July 23, 2025, Molina further slashed its full-year earnings guidance, reporting GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year-over-year, and cutting its full-year adjusted earnings guidance to no less than $19.00 per diluted share, representing a 13.6% cut from the previous guidance [7][8]. - This led to a significant drop in Molina's stock price by $32.03, or 16.84%, closing at $158.22 per share on July 24, 2025, also on unusually heavy trading volume [8].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In CarMax To Contact Him Directly To Discuss Their OptionsIf you suffered losses in CarMax between June 20, 2025 and September 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - November 16, 2025) - Faruqi & Far ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Marex Group plc due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a federal class action by December 8, 2025 [2][5]. Group 1: Allegations Against Marex - The complaint alleges that Marex and its executives made false or misleading statements and failed to disclose critical information, including the sale of over-the-counter financial instruments to itself and inconsistencies in financial statements [5]. - Specific allegations include a multi-year accounting scheme involving off-balance-sheet entities, fictitious transactions, and misleading disclosures to hide losses and inflate profits, with examples such as a $17 million fabricated receivable and nearly $1 billion in concealed derivatives exposure [6]. - Following the release of a damaging report by NINGI Research, Marex's stock experienced a significant decline of 6.2%, closing at $35.31 [7]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased Marex securities between May 16, 2024, and August 5, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1]. - The role of lead plaintiff in the class action is designated to the investor with the largest financial interest, who will oversee the litigation on behalf of the class [8]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Marex's conduct [9].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against James Hardie Industries plc due to allegations of misleading investors regarding the performance of its North America Fiber Cement segment between May 20, 2025, and August 18, 2025 [5][2]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in James Hardie to contact them directly to discuss their legal options [1]. - A federal securities class action has been filed against James Hardie, with a deadline of December 23, 2025, for investors to seek the role of lead plaintiff [2][7]. - The complaint alleges that James Hardie and its executives violated federal securities laws by making false statements and failing to disclose the true state of demand in their key segment [5]. Group 2: Financial Impact - On August 19, 2025, James Hardie reported a 29% decline in first-quarter profit and projected lower-than-expected earnings for fiscal 2026 due to high borrowing costs [5]. - Following the announcement of these financial results, the price of James Hardie's American Depositary Receipt (ADR) fell by $9.79, or 34.44%, closing at $18.64 on August 20, 2025 [6]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International Inc. due to allegations of false and misleading statements regarding the Novum LVP medical device, which has been linked to serious malfunctions and patient risks [2][5]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Baxter between February 23, 2022, and July 30, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Baxter, with a deadline of December 15, 2025, for investors to seek the role of lead plaintiff [2]. Group 2: Allegations Against Baxter - The complaint alleges that Baxter and its executives violated federal securities laws by failing to disclose systemic defects in the Novum LVP, which caused malfunctions that could lead to serious injury or death [5]. - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of product withdrawal from the market [5]. Group 3: Stock Impact - The extent of the alleged fraud was revealed on July 31, 2025, when Baxter announced a voluntary pause in shipments and installations of the Novum LVP, resulting in a 22.4% drop in stock price, closing at $21.76 [6].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit for securities fraud following a significant stock drop attributed to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - A class action lawsuit has been filed against Inspire Medical Systems and certain senior executives, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - Investors have until January 5, 2026, to request to lead the case in the U.S. District Court for the District of Minnesota [3]. Group 2: Company Background - Inspire Medical Systems develops an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Stock Performance and Issues - Inspire assured investors of a timely launch for Inspire V, but failed to prepare clinicians and payors adequately, leading to delays and weak demand due to excess inventory of older devices [5][6]. - On August 4, 2025, Inspire announced an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price dropped by $42.04, or more than 32%, from $129.95 to $87.91 per share [8].

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc for securities fraud, following a significant stock drop attributed to potential violations of federal securities laws [2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of Illinois, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [4]. - Investors have until December 23, 2025, to request to be appointed to lead the case [4]. Group 2: Company Background - James Hardie is a producer and marketer of high-performance fiber cement building solutions, primarily used in external siding for the residential building industry in the U.S. and Canada [5]. Group 3: Allegations and Stock Impact - The company previously claimed strong performance in its North American fiber cement segment, but it is alleged that sales were inflated due to inventory loading by channel partners rather than genuine customer demand [6]. - On August 19, 2025, James Hardie reported a 12% decline in North American fiber cement sales, leading to a stock price drop of over 34%, from $28.43 to $18.64 per share [7].

Core Viewpoint - CarMax, Inc. is facing a class action lawsuit for securities fraud following a significant drop in stock price attributed to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - A class action lawsuit has been filed against CarMax and certain senior executives, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - Investors have until January 2, 2026, to request to lead the case, which is pending in the U.S. District Court for the District of Maryland [3]. Group 2: Financial Performance - CarMax reported disappointing financial results for Q2 of fiscal year 2026, including a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units [6]. - The net income for the second quarter was approximately $95.4 million, down from $132.8 million in the previous year [6]. Group 3: Stock Price Impact - Following the announcement of disappointing financial results on September 25, 2025, CarMax's stock price dropped by $11.45 per share, or roughly 20%, from $57.05 to $45.60 [7]. - The unexpected departure of CEO Bill Nash on November 6, 2025, along with a weak preliminary Q3 2025 outlook, led to an additional stock price drop of over 24% [7]. Group 4: Market Context - CarMax had previously promoted strong demand for its vehicles, which was allegedly boosted by customers purchasing cars ahead of U.S. tariffs [4]. - The lawsuit suggests that the company may not have accurately assessed or reserved for its portfolio of car loans, raising further concerns about its financial practices [5].

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - Investors have until December 30, 2025, to request to lead the case in the U.S. District Court for the Northern District of California [3]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of Synopsys investors [3]. Group 2: Company Performance - Synopsys provides design automation software and has seen its Design IP segment grow from 25% of revenue in 2022 to 31% in 2024 [4]. - The company reported a revenue of $425.9 million for its Design IP segment in Q3 2025, reflecting a 7.7% year-over-year decline, and a net income of $242.5 million, down 43% year-over-year [6]. Group 3: Market Reaction - Following the release of disappointing Q3 2025 results, Synopsys stock fell nearly 36%, from $604.37 per share to $387.78 per share [6]. - The decline was attributed to customers requiring more customization for IP components, which negatively impacted the business model [5][6].